Xhance
Drug
Optinose US, Inc.
Total Payments
$9.7M
Transactions
105,664
Doctors
14,798
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 14,039 | 5,593 |
| 2023 | $866,535 | 13,743 | 4,334 |
| 2022 | $1.7M | 23,231 | 5,849 |
| 2021 | $1.5M | 19,981 | 6,071 |
| 2020 | $1.1M | 11,765 | 3,884 |
| 2019 | $2.2M | 17,131 | 5,140 |
| 2018 | $1.0M | 5,774 | 2,660 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.2M | 2,599 | 43.6% |
| Food and Beverage | $2.2M | 99,554 | 23.0% |
| Consulting Fee | $1.6M | 774 | 16.5% |
| Travel and Lodging | $819,514 | 2,456 | 8.4% |
| Honoraria | $447,300 | 211 | 4.6% |
| Unspecified | $211,716 | 20 | 2.2% |
| Space rental or facility fees (teaching hospital only) | $117,585 | 38 | 1.2% |
| Education | $32,000 | 8 | 0.3% |
| Grant | $15,000 | 3 | 0.2% |
| Charitable Contribution | $100.00 | 1 | 0.0% |
Payments by Type
General
$9.5M
105,644 transactions
Research
$211,716
20 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Investigator Sponsored Study (IIS) | Optinose US, Inc. | $103,669 | 0 |
| CS-2201 Study | Optinose US, Inc. | $66,993 | 0 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. | Optinose US, Inc. | $22,504 | 0 |
| CS2201 | OptiNose US, Inc. | $10,549 | 1 |
| A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 | Optinose US, Inc. | $8,000 | 0 |
Top Doctors Receiving Payments for Xhance — Page 591
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Family Medicine | Festus, MO | $11.13 | 1 |
| , M.D | Emergency Medicine | Festus, MO | $11.13 | 1 |
| , MD | Otolaryngology | Paris, TX | $11.13 | 1 |
| , M.D., F.A.C.S | Plastic Surgery within the Head & Neck | Mcallen, TX | $11.11 | 1 |
| , MD | Pulmonary Disease | Camillus, NY | $11.11 | 1 |
| , FNP | Family | Alexandria, VA | $11.09 | 1 |
| , DO | Student in an Organized Health Care Education/Training Program | Edmond, OK | $11.08 | 1 |
| , DO | Family Medicine | Edmond, OK | $11.08 | 1 |
| , MD | Facial Plastic Surgery | Edmond, OK | $11.08 | 1 |
| , MD | Allergy & Immunology | Rome, NY | $11.06 | 1 |
| , M.D | Otolaryngology | Chicago, IL | $11.06 | 1 |
| , MD | Family Medicine | Peoria Heights, IL | $11.06 | 1 |
| , APRN, FNP-BC | Family | Weslaco, TX | $11.05 | 1 |
| , FNP | Family | Weslaco, TX | $11.04 | 1 |
| , MD | Specialist | Merrillville, IN | $11.04 | 1 |
| Francisco Lugo | Family | Brownsville, TX | $11.04 | 1 |
| , MD | Otolaryngology | Raleigh, NC | $11.02 | 1 |
| , DO | Orthopaedic Surgery | Battle Creek, MI | $11.02 | 1 |
| , M.D | Critical Care Medicine | Burleson, TX | $11.01 | 1 |
| , MD | Pulmonary Disease | Bayonne, NJ | $11.00 | 1 |
| , MD | Otolaryngology | Troy, AL | $10.99 | 1 |
| , D.O | Family Medicine | Omaha, NE | $10.97 | 1 |
| , MD | Otolaryngology | Tulsa, OK | $10.97 | 1 |
| , M.D | Facial Plastic Surgery | Coos Bay, OR | $10.91 | 1 |
| , MD | Allergy & Immunology | Des Plaines, IL | $10.90 | 1 |
Ad
Manufacturing Companies
- OptiNose US, Inc. $4.9M
- Optinose US, Inc. $4.8M
Product Information
- Type Drug
- Total Payments $9.7M
- Total Doctors 14,798
- Transactions 105,664
About Xhance
Xhance is a drug associated with $9.7M in payments to 14,798 healthcare providers, recorded across 105,664 transactions in the CMS Open Payments database. The primary manufacturer is Optinose US, Inc..
Payment data is available from 2018 to 2024. In 2024, $1.3M was paid across 14,039 transactions to 5,593 doctors.
The most common payment nature for Xhance is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($4.2M, 43.6% of total).
Xhance is associated with 5 research studies, including "Investigator Sponsored Study (IIS)" ($103,669).